RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy

Prostate Cancer Clinical Trial

— RAD1801  

Official title:

Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03458234
• Other study ID #: IRB-300002183
• Secondary ID: 000521070
• Status: Terminated
• Phase: N/A
• Start date: January 28, 2020
• Est. completion date: June 22, 2023

Study information

• Verified date: May 2024
• Source: University of Alabama at Birmingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study offers focal therapy for prostate cancer by using an intra-urethral radiotransponder temporarily placed during radiotherapy. The study aims to improve the risk-benefit ratio of therapy for early prostate cancer and potentially lessen symptom burden over time.

Description:

This study offers focal stereotactic body radiotherapy for prostate cancer by using an intra-urethral radiotransponder placed temporarily during each of the 5 radiotherapy treatments. The study aims to improve the risk-benefit ratio of therapy for early prostate cancer and potentially lessen symptom burden over time while also accessing early efficacy, late toxicity, and overall quality of life post-treatment. Patients will be followed for 24 months (2 years) with follow-up appointments at 3, 6, 9, 12, 18, and 24 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: June 22, 2023
• Est. primary completion date: April 20, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• All patients must have histologically confirmed adenocarcinoma of the prostate, with biopsies obtained within 12 months of registration

• Gleason score 3+3 or 3+4

• PSA <10 ng/mL within 3 months of enrollment

• Clinical stage T1a-T2a by digital rectal exam

• Up to 2 intraprostatic nodules visible on MRI, with combined volume <50% of the total prostate volume

• Karnofsky Performance Status (KPS) >70%.

• Life expectancy >10 years

• Age = 19 years

• Subjects given written informed consent

Exclusion Criteria:

• >2 MRI defined nodules representing prostate cancer

• Total volume of MRI nodules exceeding 50% of total prostate volume

• Positive biopsy core in sextant region without MRI defined nodule (i.e. biopsy proven MRI occult prostate cancer)

• American Urological Association (AUA) urinary score = 18.

• History of inflammatory bowel disease.

• Prior pelvic surgery

• Prior treatment for prostate cancer

• Patients using immunosuppressive medications or other medications that may increase radiation toxicity such as methotrexate, sirolimus, tacrolimus, or colchicine that are unable to discontinue these medications during SBRT course. Use of corticosteroids is not considered an exclusion criteria.

• Platelet count < 70,000/µL

• Patients unable to discontinue anti-platelet or anti-coagulant medicine such as clopidogrel, dabigatran, warfarin, or low molecular weight heparin. Use of aspirin is not an exclusion criteria.

• Contraindication to MRI such as implanted devices.

• Metallic pelvic implants resulting in imaging artifact within the prostate on MRI or CT

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• 16 French Foley Catheter
A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra. Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag. Foley catheters are usually constructed out of either silicone or latex.

Locations

Country	Name	City	State
United States	Hazelrig-Salter Radiation Oncology Center	Birmingham	Alabama

Sponsors (2)

Lead Sponsor	Collaborator
University of Alabama at Birmingham	Varian Medical Systems

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Confirm the Feasibility of Focal Prostate Stereotactic Body Radiotherapy (SBRT) With Real Time Guidance by Intra-urethral Radiotransponder Beacons.	Confirm the technical feasibility of using focal prostate stereotactic body radiotherapy (SBRT) instead of traditional treatment methods using a 16-french Foley catheter and real time guidance by intra-urethral radiotransponder beacons.Feasibility will be defined as the ability of the treatment to take place as planned.	2 years
Secondary	Assess Early Efficacy	Clinically assess early efficacy for men receiving focal prostate SBRT for low and low-intermediate risk prostate cancer.Efficacy will be defined as the absence of biochemically detected (via PSA lab testing) prostate cancer or clinically detected prostate cancer	Within 6 months of completion of radiation therapy
Secondary	Assess Late Toxicity	Clinically assess late toxicity for men receiving focal prostate SBRT for low and low-intermediate risk prostate cancer. Late toxicity (defined as toxicity occurring >90 days after treatment) will be assessed with regular clinical exams and patient toxicity questionnaires.	Within 6 months of completion of radiation therapy
Secondary	Assess Quality of Life	Clinically assess quality of life for men receiving focal prostate SBRT for low and low-intermediate risk prostate cancer. Late quality of life will be assessed with regular clinical exams and patient quality of life questionnaires.	Within 6 months of completion of radiation therapy